--- title: "Kairos Pharma (KAPA) news: reverse split, offering and merger" url: "https://aibio.space/companies/kairos-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KAPA reverse split, offering and merger news: Kairos Pharma sets 1-for-7 reverse stock split effective September 1, 2026. Kairos Pharma, Ltd." --- KAPA Kairos Pharma, Ltd. AMEX · United States # Kairos Pharma (KAPA) news KAPA reverse split, offering and merger news Company Updates · 2026-10-06 ## [Kairos Pharma reports positive interim Phase 2 data for ENV-105 in prostate cancer](https://aibio.space/news/kairos-pharma-reports-positive-interim-phase-2-data-env-105-prostate/) Kairos Pharma says median progression-free survival was 17.7 months with ENV-105 plus apalutamide, compared with 2 months on apalutamide alone, and has changed the trial to enroll patients earlier. ## Latest Kairos Pharma news 1. 2026-08-21 Listings [Kairos Pharma sets 1-for-7 reverse stock split effective September 1, 2026](https://aibio.space/news/kairos-pharma-sets-1-7-reverse-stock-split-effective-september-1-2026/) Split-adjusted shares will trade under the existing KAPA symbol at market open on September 1, 2026, and the company says the split is meant to help it keep its NYSE American listing. 2. 2026-07-22 Company Updates [Kairos Pharma announces Bayer collaboration to test ENV-105 with XOFIGO](https://aibio.space/news/kairos-pharma-announces-bayer-collaboration-test-env-105-xofigo/) The collaboration will evaluate ENV-105 with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer involving bone, and the company cites a $570M to $1.3B addressable global market. 3. 2026-07-15 Company Updates [Kairos Pharma reports interim Phase 1 safety data for ENV-105 in lung cancer](https://aibio.space/news/kairos-pharma-reports-interim-phase-1-safety-data-env-105-lung-cancer/) The company reports no serious adverse events, defined as Grade 3 or higher, in 13 patients treated with ENV-105 and osimertinib, and says the safety profile supports progression toward an early efficacy readout. 4. 2026-06-04 Company Updates [Kairos Pharma signs CL-741 term sheet and lists milestones for 2026](https://aibio.space/news/kairos-pharma-signs-cl-741-term-sheet-lists-milestones-2026/) Kairos Pharma has signed a term sheet to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor, from privately held Celyn Therapeutics, Inc., and has listed the milestones it expects for the rest of 2026. 5. 2025-03-28 Distress [Kairos Pharma delays annual report for 2024](https://aibio.space/news/kairos-pharma-delays-annual-report-2024/) The company expects to file within the 15-day extension period after its accounting staff finalizes the statements. 6. 2025-01-17 Financings [Kairos Pharma closes $3,497,500 private placement of pre-funded units and warrants](https://aibio.space/news/kairos-pharma-closes-3-497-500-private-placement-pre-funded-units/) Kairos Pharma (NYSE American: KAPA) sold 2,500,000 pre-funded units, each with a common warrant at $1.40 per share. Boustead Securities and D. Boral Capital were co-placement agents. ## Kairos Pharma at a glance - **Ticker**: KAPA - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $2.6 million ### Related companies - [Harbor Diversified](https://aibio.space/companies/harbor-diversified/) OTC: HRBR - [Atea Pharmaceuticals](https://aibio.space/companies/atea-pharmaceuticals/) NASDAQ: AVIR - [RISING BIOSCIENCES INC](https://aibio.space/companies/rising-biosciences/) OTC: RBII - [Immuneering](https://aibio.space/companies/immuneering/) NASDAQ: IMRX - [Lipocine](https://aibio.space/companies/lipocine/) NASDAQ: LPCN - [Acumen Pharmaceuticals](https://aibio.space/companies/acumen-pharmaceuticals/) NASDAQ: ABOS - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) NASDAQ: AVLN ### Also on AMEX - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) MTNB - [NanoViricides](https://aibio.space/companies/nanoviricides/) NNVC - [AIM ImmunoTech](https://aibio.space/companies/aim-immunotech/) AIM - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) CLDI - [Impact BioMedical](https://aibio.space/companies/impact-biomedical/) IBO - [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) ARMP ## What Kairos Pharma does Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome immune suppression and drug resistance. Its candidates include antibodies and small molecules for prostate cancer, lung cancer, breast cancer and glioblastoma, and the company describes a seven-drug portfolio. Its proprietary technologies are licensed from Cedars-Sinai Medical Center. Through its Enviro Therapeutics, Inc. subsidiary, acquired in June 2021, it holds ENV 105, a biologic that targets endoglin and is designed to address resistance to androgen targeted drugs and EGFR inhibitors, and ENV 205, a pre-clinical therapeutic for chemotherapy resistance and cachexia. ENV 105 is in a Phase 1 trial for non-small cell lung cancer and a randomized Phase 2 trial for prostate cancer, both started in September 2023. An earlier Phase 2 trial at Cedars-Sinai in heavily pre-treated prostate cancer patients reported a clinical benefit rate of 62%, and enrollment closed before the planned 40 patients because of limited drug supply. KROS 201, a T cell therapy for glioblastoma, is also in clinical trials. KROS 101 is a small molecule that targets the GITR ligand. | Product or program | What it is | Stage | |---|---|---| | ENV 105 | Biologic targeting endoglin, for resistance to androgen targeted drugs and EGFR inhibitors | Phase 1 in non-small cell lung cancer; randomized Phase 2 in prostate cancer | | KROS 201 | Activated T cell therapy for glioblastoma | Clinical trial started fall 2023 | | KROS 101 | Small molecule that targets the GITR ligand | Pre-clinical or clinical-trial stage | | ENV 205 | Therapeutic for chemotherapy resistance and cachexia | Pre-clinical | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm). ## Kairos Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) | [$414,000](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) | | Net income (loss) | [-$5.4 million](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) | [-$2.6 million](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) | | Cash from operations | [-$3.4 million](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) | [-$4.0 million](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) | | Cash and equivalents | [$4.5 million](https://www.sec.gov/Archives/edgar/data/1962011/000149315226037355/) | [$1.3 million](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Kairos Pharma Did Kairos Pharma do a reverse stock split? Our latest story on this, dated Aug 21, 2026: "Kairos Pharma sets 1-for-7 reverse stock split effective September 1, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kairos-pharma-sets-1-7-reverse-stock-split-effective-september-1-2026/). Has Kairos Pharma raised money recently? Our latest story on this, dated Jan 17, 2025: "Kairos Pharma closes $3,497,500 private placement of pre-funded units and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kairos-pharma-closes-3-497-500-private-placement-pre-funded-units/). Is Kairos Pharma involved in a merger or acquisition? Our latest story on this, dated Jun 4, 2026: "Kairos Pharma signs CL-741 term sheet and lists milestones for 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/kairos-pharma-signs-cl-741-term-sheet-lists-milestones-2026/). What is the ticker symbol of Kairos Pharma? Kairos Pharma, Ltd. trades under the ticker KAPA on AMEX. Where is Kairos Pharma listed? Kairos Pharma, Ltd. is listed on AMEX. What is the SEC CIK of Kairos Pharma? The SEC Central Index Key (CIK) for Kairos Pharma, Ltd. is 1962011. Its filings are on SEC EDGAR. How many shares does Kairos Pharma have outstanding? 23,697,683 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Kairos Pharma listed under? Our directory records Kairos Pharma, Ltd. under United States. What does Kairos Pharma do? Our directory classifies Kairos Pharma, Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Kairos Pharma? The ISIN recorded for Kairos Pharma, Ltd. is US48301N2036. Does aibio.space cover Kairos Pharma? aibio.space lists Kairos Pharma, Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Kairos Pharma incorporated? SEC records list its state or country of incorporation as DE. What does Kairos Pharma develop? Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome immune suppression and drug resistance. Its candidates include antibodies and small molecules for prostate cancer, lung cancer, breast cancer and glioblastoma, and the company describes a seven-drug portfolio. What is ENV 105 from Kairos Pharma? ENV 105: Biologic targeting endoglin, for resistance to androgen targeted drugs and EGFR inhibitors Stage: Phase 1 in non-small cell lung cancer; randomized Phase 2 in prostate cancer. What is KROS 201 from Kairos Pharma? KROS 201: Activated T cell therapy for glioblastoma Stage: Clinical trial started fall 2023. ## Investor discussion: Kairos Pharma Members talk about Kairos Pharma (KAPA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Kairos Pharma, newest first. Each line links the filing it comes from. 1. 2026-08-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1962011/000149315226039695/ex99-1.htm) 2. 2026-06-30 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1962011/000149315226031328/form8-k.htm) 3. 2026-05-22 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1962011/000149315226025020/formdef14a.htm) 4. 2026-05-11 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1962011/000149315226022194/formpre14a.htm) 5. 2026-01-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1962011/000149315226001909/forms-3.htm) 6. 2025-04-28 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1962011/000164117225006504/form8-k.htm) 7. 2025-04-24 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/ex99-1.htm) 8. 2025-03-28 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1962011/000164117225001186/formnt10-k.htm) 9. 2025-01-29 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1962011/000149315225004041/forms-1.htm) 10. 2024-11-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1962011/000149315224045671/form10-q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:KAPA on TradingView](https://www.tradingview.com/symbols/AMEX-KAPA/). ## SEC filings and registration - **SEC name**: Kairos Pharma, LTD. - **CIK**: 1962011 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: KAPA (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064 - **Phone**: 818-404-5541 - **Shares outstanding**: 23,697,683 as of 2026-08-12 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/form8-k.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226042569/form8-k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226039695/form8-k.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1962011/000149315226037355/form10-q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/form8-k.htm) filed 2026-07-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/form8-k.htm) filed 2026-07-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226031328/form8-k.htm) filed 2026-06-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226027200/form8-k.htm) filed 2026-06-04 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001962011), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Kairos Pharma, Ltd. is a public biotech or pharmaceutical company listed on AMEX under the ticker KAPA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Kairos Pharma, Ltd. - **Ticker**: KAPA - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US48301N2036 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-KAPA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/kairos-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kairos Pharma (KAPA) news: reverse split, offering and merger", 2026-10-31, https://aibio.space/companies/kairos-pharma/